Regulation of Monocarboxylic Acid Transporter 1 Trafficking by the Canonical Wnt/β-Catenin Pathway in Rat Brain Endothelial Cells Requires Cross-talk with Notch Signaling*"°

The transport of monocarboxylate fuels such as lactate, pyruvate, and ketone bodies across brain endothelial cells is mediated by monocarboxylic acid transporter 1 (MCT1). Although the canonical Wnt/β-catenin pathway is required for rodent blood-brain barrier development and for the expression of associated nutrient transporters, the role of this pathway in the regulation of brain endothelial MCT1 is unknown. Here we report expression of nine members of the frizzled receptor family by the RBE4 rat brain endothelial cell line. Furthermore, activation of the canonical Wnt/β-catenin pathway in RBE4 cells via nuclear β-catenin signaling with LiCl does not alter brain endothelial Mct1 mRNA but increases the amount of MCT1 transporter protein. Plasma membrane biotinylation studies and confocal microscopic examination of mCherry-tagged MCT1 indicate that increased transporter results from reduced MCT1 trafficking from the plasma membrane via the endosomal/lysosomal pathway and is facilitated by decreased MCT1 ubiquitination following LiCl treatment. Inhibition of the Notch pathway by the γ-secretase inhibitor N-[N-(3,5-difluorophenacetyl)-L-ala-nyl]-S-phenylglycine β-butyl ester negated the up-regulation of MCT1 by LiCl, demonstrating a cross-talk between the canonical Wnt/β-catenin and Notch pathways. Our results are important because they show, for the first time, the regulation of MCT1 in cerebrovascular endothelial cells by the multifunctional canonical Wnt/β-catenin and Notch signaling pathways.

Monocarboxylic acid transporter 1 (MCT1)-dependent lactate transport is critical for various biological processes, including muscle and colonocyte metabolism, kidney glomerulus function, immune suppression, tumor progression, long-term memory formation, and oligodendroglial metabolism (1–7). In the brain, MCT1 is highly expressed in the endothelial cells of the neurovascular unit and the so called blood-brain barrier (BBB)." MCT1 is responsible for the blood-brain transport of monocarboxylic substrates such as lactate, pyruvate, ketone bodies, and some monocarboxylic drugs (8–10). Furthermore, by facilitating brain-to-blood efflux of lactic acid, MCT1 represents an important pathway to reduce lactic acidosis associated with hypoxia and stroke, in which decreased lactic acidosis predicts a better prognosis (11, 12). MCT1-dependent delivery of ketone bodies from the peripheral circulation into the brain is especially critical for supporting neonatal brain development, maintaining energy metabolism of hibernating animals, and treating childhood epilepsy and glucose transporter 1 deficiency syndrome with the ketogenic diet (13–17). MCT1 also transports drugs into the CNS, including valproic acid to treat epilepsy and bipolar disorders (18) and 3-bromopyruvate to inhibit glycolytic tumors, implicating the transporter as an important therapeutic target (19). Therefore, understanding the regulation of brain endothelial MCT1 is of particular significance for brain health and disease.

However, research on the regulation of MCT1 by signaling pathways in brain endothelial cells is limited and merits further investigation. One signaling pathway that is crucial for initiating rodent BBB development is the canonical Wnt/β-catenin pathway (20, 21), which also plays a critical role in many other biological processes, e.g. dorsal-ventral axis formation during embryonic development, cell proliferation, tissue self-renewal, and cancer progression (22–25). Activity of the Wnt/β-catenin pathway depends on nuclear β-catenin, which is normally kept low in resting cells. An intracellular multiprotein complex consisting of adenomatous polyposis coli (APC), axin, glycogen synthase kinase 3 β (GSK-3 β), and casein kinase 1 α (CK1 α) phosphorylates cytosolic β-catenin. This phosphorylation leads to recognition and ubiquitination of β-catenin by the E3 ubiquitin ligase β-TrCP and subsequent proteasomal degradation (26, 27). Wnt ligands signal by binding to the extracellular portion of frizzled family receptors (FZDs) and low-density lipoprotein receptor-related protein 5 or 6 co-receptors. So far, 10 mammalian FZD genes and 19 highly conserved secreted Wnt ligands have been identified (28). Wnt signaling leads to

---

* This work was supported by American Heart Association Grant 0855638G to L. R. D.) and NINDS/National Institute of Health Grant 1R15NS062404 – 01A2 to J. P. S.). The authors declare that they have no conflicts of interest with the contents of this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

† This article contains supplemental Tables S1 and S2.

1 To whom correspondence may be addressed: Dept. of Internal Medicine, Section of Endocrinology, Yale School of Medicine, 300 Cedar St., New Haven, CT 06519. Tel.: 203-737-2253; Fax: 203-785-6015; E-mail: zejian.liu@yale.edu.

2 To whom correspondence may be addressed: Dept. of Biomedical Sciences, University of Minnesota Duluth, 1035 University Dr., Duluth, MN 55812. Tel.: 218-726-7925; Fax: 218-726-8014; E-mail: ldrewes@d.umn.edu. This is an Open Access article under the CC BY license.

3 The abbreviations used are: BBB, blood-brain barrier; APC, adenomatous polyposis coli; DAPT, N-[N-(3,5-difluorophenacetyl)-L-allyl]-S-phenylglycine t-butyler ester; mTOR, mammalian target of rapamycin; ANOVA, analysis of variance.
disassembly of the complex that degrades β-catenin. As a consequence, cytoplasmic β-catenin is stabilized so that it can translocate into the nucleus, where β-catenin interacts with TCF/LEF transcription factors and promotes Wnt target gene expression (29). In brain endothelial cells, these targets include CyclinD1, Lef1, c-Myc, as well as P-glycoprotein (Pgp) (30–33). Lithium inhibits the activity of GSK-3β both directly and indirectly. Consequently, lithium can be an agonist of the Wnt/β-catenin pathway (34). In contrast, quercetin antagonizes this pathway by blocking nuclear translocation of β-catenin (35). In many situations, the Wnt/β-catenin pathway is affected by the Notch pathway, either positively or negatively (36–41). Whether or not the cross-talk exists in endothelial cells of the BBB is still unknown.

The Notch pathway is highly conserved across the animal kingdom and functions in determining cell fates during development (42). The binding of Notch ligand to its receptor on the Notch pathway, the BBB is still unknown.

Therefore, given the significance of brain endothelial MCT1 for brain functions, the critical role of the canonical Wnt/β-catenin pathway in BBB development (42). The binding of Notch ligand to its receptor on the BBB is still unknown. The Notch pathway, the BBB is still unknown.

**Experimental Procedures**

**Cell Culture**—RBE4 cells were cultured as described previously (48, 49) in a humidified incubator at 37 °C with 5% CO₂. All experiments were conducted when the cells reached 80–90% confluence.

**Reagent Stocks**—1 m lithium chloride (Sigma-Aldrich, L-0505), 1 m NaCl (Fisher Scientific, S640-3), 40 µg/ml Wnt3a recombinant protein (R&D Systems, 1324-WN-002), and 20 mM chloroquine diphosphate (Sigma-Aldrich, C6628) stocks were all made in H₂O, sterile-filtered, and stored at 4 °C. 1 m quercetin dihydrate (EMD Millipore, 551600), 50 mM SB216763 (Sigma-Aldrich, S3442), 10 mM MG132 (Sigma-Aldrich, C2211), 10 mM clasto-lactacystin β-lactone (EMD Millipore, 426102), and 50 mM DAPT (Sigma-Aldrich, 5942) stocks were all made in dimethyl sulfoxide (Sigma-Aldrich, D2650) and stored at −80 °C until use.

**RNA Isolation, Reverse Transcription, PCR, and RT-PCR**—Total RNA was isolated using the RNEasy mini kit (Qiagen, 74104) according to the instructions of the manufacturer. RNA samples were converted to cDNA using the QuantiTect reverse transcription kit (Qiagen, 205311). Benchtop PCR was performed in a GeneAmp® PCR System 9700 machine using Platinum TaqDNA polymerase (Invitrogen, 10966-034) within a 50-µl reaction volume: 1 × PCR buffer (−Mg²⁺), 0.2 mM dNTP (each), 1.5 mM MgCl₂, 0.2 µM primer (each), 50 ng of template cDNA, and 0.5 µl of Taq. The cycling parameters used were as follows: initial 94 °C for 1 min, followed by 30 cycles of 94 °C for 30 s and 72 °C for 1.5 min, an additional extension at 72 °C for 7 min, and finally hold at 4 °C. The PCR products were resolved by electrophoresis on SeaKem agarose gel (Lonza, 50152) supplemented with ethidium bromide in 1 × TAE buffer (40 mM Tris, 20 mM acetic acid, and 1 mM EDTA). Rotor Gene Cyber Green-based (Qiagen, 204074) RT-PCR was conducted on a Rotor Gene RG-3000 cycler (Corbett Research) using 50 ng of total cDNA per reaction with the following settings: 95 °C for 5 min, followed by 95 °C for 5 s and 60 °C for 10 s for 40 cycles. The RT-PCR results were analyzed using the cycle threshold method (Cₜ, Applied Biosystems User Bulletin No. 2, P/N 4303859) and expressed as -fold change over control. All primers used here were designed through the PrimerQuest tool from Integrated DNA Technologies (supplemental Table S1).

**Restriction Enzyme Digestion**—Restrictive digestions of PCR products were performed by incubation in a 37 °C water bath for at least 2 h in a 20-µl reaction system: final 1× buffer, 2 µl of PCR DNA product, 0.1 µg/µl BSA, and 0.5 µl of specific restriction enzymes. The digests were analyzed by electrophoresis.

**siRNA Knockdown**—RBE4 cells were transfected with or without validated rat β-catenin siRNA (Dharmacon, L-100628-02-0005) at a final concentration of 25 nM in the presence of DharmaFECT transfection reagent in serum/antibiotic-free medium. After 24 h, cells were moved into complete culturing medium and treated with 20 mM LiCl for another 24 h. Whole cellular proteins were then harvested.

**Protein Lysate Preparation**—Whole cellular protein samples were prepared by direct in-flask scraping of cells using SDS boiling buffer (5% SDS, 10% v/v glycerol, 60 mM Tris-Cl (pH 6.8)), followed by homogenization and centrifugation at 13,000 rpm for 10 min. Nuclear protein samples were prepared according to procedures reported previously (50). Briefly, monolayer cells were scraped off flasks, pelleted, and resuspended in Nonidet P-40 lysis buffer (0.3% Nonidet P-40, 1 mM HEPES (pH 7.9), 1.5 mM MgCl₂, 10 mM potassium chloride, 0.5 mM DTT, and 1× protease inhibitor mixture). After centrifugation at 13,000 rpm for 10 min, the pelleted nuclei were lysed using a high-salt buffer (20 mM HEPES (pH 7.9), 25% v/v glycerol, 0.42 mM NaCl, 1.5 mM MgCl₂, and 0.2 mM EDTA). All protein samples were stored at −80 °C until use.

**Western Blotting**—Protein concentrations were determined using the Pierce BCA protein assay kit (Thermo Scientific, 23227) unless otherwise mentioned. Western blotting was performed as reported previously (51). Specifically, equal amounts of proteins were subjected to SDS-PAGE electrophoresis on Criterion TGX precast gels (Bio-Rad, 5671033) and transferred to supported nitrocellulose membranes (Bio-Rad, 162-0070). The membranes were blocked for 1 h in 5% BSA for anti-ubiquitin antibody or Sea Block (Thermo Scientific, 37527) for all other antibodies, followed by overnight incubation at 4 °C with primary antibody diluted 1:5000 for anti-MCT1 (10), 1:5000 for
anti-Actin (EMD Millipore, MAB1501), 1:1000 for anti-ubiquitin (Enzo, BML-PW8810), 1:20,000 for anti-β-catenin (EMD Millipore, ABE208), and 1:500 for anti-Histone H1 (Santa Cruz Biotechnology, sc-10806) in blocking buffer. Then the membranes were incubated for 1 h with rabbit anti-chicken IgY secondary antibody (Thermo Scientific, 31401) diluted 1:5000 for MCT1, goat anti-mouse IgG secondary antibody (Thermo Scientific, 31430) diluted 1:10,000 for Actin and 1:5000 for ubiquitin, and goat anti-rabbit IgG secondary antibody (Thermo Scientific, 31462) diluted 1:10,000 for β-catenin and 1:5000 for Histone H1. Detection was accomplished after membranes were rinsed in SuperSignal West Pico chemiluminescent substrate (Thermo Scientific, 34080).

Plasmid Cloning and Transfection—The GST-Mct1 fusion vector was generated using the Gateway cloning method according to the instructions of the vendor (Life Technologies). Briefly, the Mct1 attB-PCR product was obtained from a cDNA library of RBE4 cells using the forward and reverse primers GGGGACAAAGTTGTACAAAAAAGCAGGCTCATGCC-ACCTGCGATTTGGA and GGGGACACTTTGTAACAAGAAA-AGCTGTTGGTTACAGCTGGCTCTCTCTC, respectively. BP recombination (Gateway cloning, Life Technologies) was then performed using the attB-PCR product and pDONR221 to generate the entry vector, which was used in the subsequent LR recombination reaction with pDEST27 vector to create the final expression clone. Rat mCherry-Mct1 vector was cloned as described previously (52). The integrity of all vectors was confirmed by sequencing.

Transfection of DNA vectors into RBE4 cells was conducted using Lipofectamine LTX with Plus (Invitrogen, 15338-100) according to the manual of the vendor. Briefly, the cells were exposed to the transfection complex, consisting of 1 ng/μl DNA, 1 μl/ml Plus reagent, and 4 μl/ml Transfectamine LTX reagent in growth medium, for 4 h before changing for fresh antibiotic-free medium. For GST-Mct1 transfection, fresh medium was replaced 48 h later with or without 20 mM LiCl for an additional 24 h. For mCherry-Mct1 transfection, cells were trypsinized and reseded at a density of 3 × 10^6 cells/well into μ-Slide 8-well plates (Ibidi, 80821) that were precoated with collagen. These replated cells were cultured for an additional 24 h before they were treated with LiCl.

Confocal Microscopy—Confocal images were collected on a laser-scanning confocal microscope (Zeiss LSM710). Transfected RBE4 cells growing in μ-Slide 8-well plates were directly imaged using the following configurations: ×40 objective with H2O immersion, built-in settings for mCherry fluorescence (561-nm laser), scan mode as frame, frame size 512X512, averaging method as mean, number as 4 and mode as frame, 12-bit depth, and 1 airy unit.

Cell Surface Protein Isolation—Cell surface proteins were prepared using the Pierce cell surface protein isolation kit (Thermo Scientific, 89881). Specifically, RBE4 cells growing in collagen-coated flasks (Corning Inc., 430725) were labeled with Sulfo-NHS-SS-Biotin. Then cells were scraped off, centrifuged to pellet, and resuspended in lysis buffer. The resulting lysates were spun at 13,000 rpm at 4 °C, and the supernatant was incubated with NeutrAvidin-agarose. The biotinylated proteins were eluted off the agarose beads using SDS-PAGE sample buffer (Thermo Scientific, 39001) supplemented with 50 mM DTT. The Pierce 660-nm protein assay (Thermo Scientific, 22662) was used for determining the concentrations of the eluates.

GST Pulldown Assay—RBE4 Cells transfected with the GST-Mct1 plasmid were harvested in radioimmune precipitation assay lysis buffer supplemented with protease inhibitor mixture (Roche) and N-ethylmaleimide. The clarified supernatant was first precleared for nonspecific binding by incubation with Sephadex 4B (Sigma-Aldrich) resin and then incubated with glutathione-Sepharose resin (GE Healthcare, 17075601) at 4 °C. The captured proteins were eluted off the beads in Laemmli sample buffer (Bio-Rad, 1610737).

Results

The Canonical Wnt/β-Catenin Pathway Up-regulated MCT1 Protein Expression in RBE4 Cells—To test our hypothesis that brain endothelial MCT1 can be regulated by the canonical Wnt/β-catenin pathway, we first determined the expression profile of the 10 frizzled receptors in our RBE4 cell model by using benchtop PCR amplification of cDNA that was reverse-transcribed from total RNA. The expected sizes of PCR products for Fzd1–10 were 547, 527, 544, 669, 503, 588, 647, 301, 600, and 614 bp, respectively (supplemental Table S2). Electrophoresis of the PCR products revealed mRNA for all receptors except Fzd10 to be expressed in RBE4 cells (Fig. 1A). The specificity of each PCR product was further confirmed by restriction enzyme digestion. All digests gave the expected bands for each receptor gene examined (Fig. 1B), implying the potential for Wnt/β-catenin signaling activation in RBE4 cells.

Then we treated RBE4 cells for 24 h with vehicle control, 20 mM NaCl (as an osmotic control), or 20 mM LiCl in the presence or absence of 80 μM quercetin and examined MCT1 expression in the whole cell lysates by Western blotting. Compared with NaCl, LiCl significantly increased the MCT1 protein level by 50%, which was negated by co-treatment with quercetin (Fig. 1C). In accordance, LiCl increased nuclear accumulation of β-catenin by 300%, which was reduced by 80 μM quercetin (Fig. 1D). Furthermore, siRNA-mediated knockdown of β-catenin significantly decreased the protein level of β-catenin and negated the up-regulation of MCT1 by LiCl (Fig. 1E). Our results demonstrated the specific requirement of nuclear β-catenin-mediated signaling transduction in the observed up-regulation of MCT1 by LiCl. Similarly, treatment of RBE4 cells for 48 h with 5 μM SB216763, another commercial GSK-3 β inhibitor, increased MCT1 protein expression by 35% (Fig. 1F). Finally, treatment of RBE4 cells for 9 h with 100 ng/ml recombinant Wnt3a, the canonical Wnt ligand that is required for rodent BBB development (20), stabilized β-catenin and increased MCT1 protein expression by 40% (Fig. 1G). In summary, our results showed that activation of the canonical Wnt/β-catenin pathway elevated MCT1 protein level in RBE4 cells.

The Canonical Wnt/β-Catenin Pathway Did Not Alter the mRNA Level of Mct1—To determine the mechanisms for MCT1 up-regulation by the canonical Wnt/β-catenin pathway, we first performed RT-PCR to examine the transcriptional level of Mct1. Although LiCl induced expression of well known Wnt target genes as expected, e.g. CyclinD1, Lef1, and Pgp, it did not
change the mRNA level of Mct1 (Fig. 2A). Therefore, the canonical Wnt/β-catenin pathway up-regulated MCT1 protein expression independently of affecting Mct1 transcription in RBE4 cells.

Then we hypothesized that an altered MCT1 protein turnover rate might account for its increased expression by the canonical Wnt/β-catenin pathway. Generally, membrane proteins are degraded in lysosomes and intracellular proteins in proteasomes (53, 54). To determine how MCT1 is degraded in RBE4 cells, we first treated RBE4 cells with MG132, a proteasome inhibitor. We could not detect significant changes in the level of MCT1 protein on Western blotting analyses at any dose during a 6-h treatment (0.2, 0.5, 1, and 2 μM) (Fig. 2B). Similarly, the duration of treatment was without effect at 0.2 μM (6, 12, or 24 h) (Fig. 2C). These results were confirmed by using another, more selective proteasome inhibitor, clasto-lactacystin β-lac-
The ubiquitin status of MCT1 is affected by the canonical Wnt/β-catenin pathway, we generated and transfected a GST-MCT1 fusion vector into RBE4 cells and treated them with or without 20 mM LiCl for 24 h. GST-tagged MCT1 proteins were purified by GST pulldown and subjected to SDS-PAGE electrophoresis, followed by immunoblotting against ubiquitin. We found that LiCl decreased ubiquitination of MCT1 by 90% (Fig. 3D), consistent with a reduction of MCT1 internalization from the plasma membrane after activation of the canonical Wnt/β-catenin pathway.

The Canonical Wnt/β-Catenin Pathway Increased Expression of MCT1 on the Plasma Membrane of RBE4 Cells—Our previous study revealed an endosomal/lysosomal trafficking pattern for MCT1 that was regulated by the cAMP signaling pathway (49). Furthermore, the MCT1 protein sequence contains several peptide motifs that are highly involved in the endosomal/lysosomal sorting process, such as the dileucine (LI) motif, YXXΦ motif, and acidic clusters (52, 55, 56) (Fig. 3C).

Therefore, we hypothesized that the canonical Wnt/β-catenin pathway stabilizes MCT1 by reducing its trafficking from the plasma membrane into the endosomal/lysosomal system. To test this hypothesis, we biotinylated and purified RBE4 surface proteins that were then subjected to SDS-PAGE electrophoresis, followed by immunoblotting against MCT1. We found that treatment for 24 h with 20 mM LiCl significantly increased the expression of MCT1 on the plasma membrane by 200% (Fig. 3A).

This result was confirmed by another study where RBE4 cells were transfected with an mCherry-MCT1 plasmid. In confocal micrographs, the fluorescence intensity of mCherry-tagged MCT1 on the plasma membrane was dramatically increased by 20 mM LiCl treatment for 24 h (Fig. 3B). Taken together, these data show that expression of MCT1 on the plasma membrane of RBE4 cells is increased by activation of the canonical Wnt/β-catenin pathway.

The Canonical Wnt/β-Catenin Pathway Decreased the Ubiquitination Degree of MCT1—Ubiquitination is a common post-translational modification mechanism that acts as a sorting signal for increased trafficking through the endosomal system and for proteasomal degradation of substrate proteins (57, 58). MCT1 protein contains a PY motif (PPTY) on its N terminus that has been implicated in ubiquitin E3 ligase binding and late endosome/lysosome targeting (59) (Fig. 3C). To verify whether

**FIGURE 1.** The canonical Wnt/β-catenin pathway up-regulated MCT1 protein expression in RBE4 cells. A. Wnt Fzd receptor genes that are expressed in RBE4 cells were examined using PCR amplification of cDNA that was reverse-transcribed from total RNA, followed by agarose gel analysis. Fzd1 to Fzd9, from left to right, each showed a band of the expected size (supplemental Table S2). However, Fzd10 did not generate a band (data not shown). B, the specificity of each PCR product was further confirmed by restriction enzyme digestion. All of the nine PCR digests showed the expected bands (supplemental Table S3). C, RBE4 cells were treated for 24 h with vehicle control, 20 mM NaCl, or 20 mM LiCl in the presence or absence of 80 μM quercetin dihydrate, followed by Western blotting against MCT1 in the whole cell lysates. Data were first normalized to β-actin and then expressed as –fold change over control. Compared with NaCl, LiCl increased MCT1 protein expression by 50%, which was completely blocked by quercetin (one-way ANOVA followed by Tukey’s post hoc test; mean ± S.D.; **, p < 0.05; ***, p < 0.01; ****, p < 0.001). D, RBE4 cells were treated with or without 20 mM LiCl in the presence or absence of 80 μM quercetin for 24 h. Western blotting against MCT1 in the whole cell lysates were first normalized to β-actin and then expressed as –fold change over control. LiCl dramatically increased the nuclear β-catenin level by 300%, which was reduced by quercetin (one-way ANOVA followed by Tukey’s post hoc test; mean ± S.D.; **, p < 0.05). E, RBE4 cells were first transfected with or without β-catenin siRNA for 24 h and then treated for another 24 h with vehicle control, 20 mM NaCl, or 20 mM LiCl. Western blotting analysis in whole cell lysates showed that the level of β-catenin was stabilized by LiCl but diminished after siRNA-mediated knockdown. Up-regulation of MCT1 by LiCl was negated by β-catenin siRNA (one-way ANOVA followed by Tukey’s post hoc test; mean ± S.D.; **, p < 0.01; ***, p < 0.001). F, RBE4 cells were treated for 48 h with either vehicle control (dimethyl sulfoxide) or 5 μM SB216763. Western blotting analysis showed that SB216763 increased the MCT1 protein level by 35% (Student’s t test; mean ± S.D.; **, p < 0.01). G, RBE4 cells were treated for 9 h with either vehicle control (PBS) or recombinant Wnt3a. Western blotting showed that Wnt3a stabilized β-catenin and increased the MCT1 protein level by 40% (Student’s t test; mean ± S.D.; **, p < 0.01).
were all significantly increased by LiCl, demonstrating a role of the canonical Wnt/β-catenin pathway in promoting Notch signaling transduction (Fig. 4D). Surprisingly, Hes1, one of the predominant Notch targets in RBE4 cells, was unchanged by LiCl, whereas Hey2, another predominant Notch target, was down-regulated by LiCl (Fig. 4D). In conclusion, the interplay between Wnt and Notch pathways can be complicated in RBE4 cells, probably depending on their biological contexts.

**Discussion**

In this study, we report that the canonical Wnt/β-catenin signaling pathway up-regulates MCT1 protein expression on the plasma membrane of RBE4 cells by a mechanism that
reduces ubiquitination and degradation of the transporter in the endosomal/lysosomal system. This regulation does not alter the levels of \textit{Mct1} mRNA and requires intact Notch signaling (Fig. 5). To our knowledge, this is the first report showing a regulatory effect of the canonical Wnt/\beta-Catenin pathway on MCT1.

Our discovery is consistent with recent studies showing a similar regulatory mechanism that controls MCT1 function by cAMP-dependent signaling in RBE4 cells (49, 52). Such a mechanism is supported by the critical amino acid domains (e.g. dileucine motif, acidic clusters, and YXX\_motif) present on the intracellular portion of MCT1 (Fig. 3C). These domains are strongly associated with targeting transmembrane proteins from the plasma membrane into endosomal compartments and lysosomes (55, 60, 61). For example, the intracellular sequestration of insulin-responsive glucose transporter 4 (GLUT4) in adipose tissue is at least regulated by a dileucine domain (62) as well as an acidic cluster-based motif in the C terminus (63). Thus, our results are consistent with the previous findings that cell surface transporters can be actively regulated through the endosomal/lysosomal sorting system.

Our results do not exclude the possibility that enhanced translation of \textit{Mct1} mRNA might contribute to the observed up-regulation of MCT1 protein. Indeed, GSK-3 is able to phosphorylate and activate tuberous sclerosis complex 2 (TSC2), thereby inhibiting mammalian target of rapamycin complex 1 (mTORC1) activity (64). As a result, lithium can reverse the inhibitory effect of GSK-3 and activate the mTOR signaling pathway, enhancing the capacity of protein translational machinery (65). In addition, previous studies of monocarboxy-
lic acid transporter 2 (MCT2) showed that the elevated expression of this neuronal MCT paralog is induced by noradrenaline and is mediated by translational activation of the mTOR/S6K pathway (66). However, the much greater up-regulation of MCT1 observed on the plasma membrane (200%) compared with whole cell lysates (50%) in this study favors the notion that the canonical Wnt/β-catenin pathway affects intracellular trafficking more than protein translation.

The cross-talk between Wnt and Notch pathways observed in our study is supported by previous research in mouse embryonic stem cells that demonstrated that inhibition of Notch by DAPT significantly reduces β-catenin activity by decreasing its expression.

**FIGURE 4.** The canonical Wnt/β-catenin pathway up-regulated MCT1 expression in a Notch signaling-dependent manner in RBE4 cells. A, the expression profile of genes from the Notch pathway was examined by RT-PCR and represented as –fold change to that of Gapdh using the ΔΔCt method with the formula 2−ΔΔCt = C(T gene)−C(T Gapdh). Data were summarized as mean ± S.D. *p < 0.05; ****, p < 0.0001. B, RBE4 cells were treated with vehicle control (dimethyl sulfoxide (DMSO)) or 5 μM DAPT for 24 h, followed by RT-PCR analysis. Data were first normalized to β-actin and then expressed as –fold change over vehicle control. DAPT down-regulated expression of the Notch target genes Hes1, Hey1, and Hey2 by 53%, 34%, and 54%, respectively (Student’s t test, mean ± S.D.; *, p < 0.05; ****, p < 0.0001). C, RBE4 cells were treated for 24 h with vehicle control, 20 mM LiCl alone, or 20 mM LiCl together with 5 μM or 25 μM DAPT. Whole cell lysates were prepared and separated on SDS-PAGE, followed by immunoblotting against MCT1 and Actin. Densitometry was used for quantification, and results were expressed as –fold change over vehicle control. LiCl elevated MCT1 expression by 56%, which was reduced by 5 μM DAPT and completely blocked by 25 μM DAPT (one-way ANOVA followed by Tukey’s post hoc test; mean ± S.D.; *, p < 0.05; ****, p < 0.0001). D, RBE4 cells were treated with vehicle control, 20 mM NaCl, or 20 mM LiCl for 24 h. Total RNA was prepared, reverse-transcribed, and quantified by RT-PCR. Results were first normalized to the internal standard Gapdh and then expressed as –fold change over vehicle control. LiCl up-regulated the expression of Notch4 by 8-fold, Dll3 by 3-fold, Dll4 by 15-fold, and Hes7 by 2.5-fold. In contrary, LiCl did not change the level of Hes1 and down-regulated Hey2 to 0.42-fold (one-way ANOVA followed by Tukey’s post hoc test; mean ± S.D.; *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001; ns, non-significant).
protein level (39) and thus quenches Wnt signaling. In addition, this cross-talk has also been reported extensively in cancer progression, where MCT1 functions as an important metabolic facilitator. For example, Notch is found downstream of Wnt in colorectal cancer cells, where β-catenin-mediated transcriptional activation of Notch-ligand Jagged1 promotes tumorigenesis (41). Similarly, the effect of LiCl-mediated Wnt activation on cell cycle progression in non-small-cell lung cancer cells is attenuated by siRNA knockdown of Notch3 signaling (67).

In vascular development, canonical Wnt and Notch signaling are functionally connected and control each other. Specifically, stabilization of Wnt/β-catenin signaling in endothelial cells during early embryonic development alters expression of the Dll4 ligand and causes a vascular phenotype that is similar to what is observed with the up-regulation of Notch signaling (69). Our RT-PCR data showing the up-regulation of MCT1 by the Wnt/β-catenin pathway because this up-regulation can be negated by the γ-secretase inhibitor DAPT. Co-R, co-repressor; EE, early endosome; LE, late endosome; LYS, lysosome; NICD, Notch intracellular domain; CSL, CBF1/RBP/J/Su(H)/Lag-1; MAM, Mastermind; P, phosphate group; U, ubiquitin.

In conclusion, we report that the canonical Wnt/β-catenin signaling pathyway regulates MCT1 in an immortalized rat brain endothelial RBE4 cell line. Specifically, we found that the Wnt pathway decreased the ubiquitination status of MCT1, reduced endothelial RBE4 cell line. Specifically, we found that the Wnt pathway decreased the ubiquitination status of MCT1, reduced trafficking of MCT1 within the endosomal/lysosomal system, and increased the expression of MCT1 on the plasma membrane. Intact Notch activity was indispensable in the up-regulation of MCT1 by the Wnt pathway. Our findings are highly relevant to brain development because normal development of both human and rat brain is associated with a metabolic switch from lactate and ketone bodies in the immature brain to glucose in the adult (75). Because the Wnt pathway maintains the characteristics of rodent BBB during embryonic and postnatal development (20), our findings now provide an explanation for how brain endothelial MCT1 is regulated to help with the metabolic reliance of immature brain on monocarboxy...
lates. Furthermore, these results may have important implications for developing therapeutic strategies for disorders where an enhanced transport of alternative fuels or monocarboxylic drugs across the BBB can serve as a potential treatment.

**Author Contributions**—Z. L. designed and conducted most of the experiments, analyzed the results, and wrote most of the manuscript. M. S. conducted the experiments on Wnt3a, GST pulldown, and siRNA knockdown. T. A. H. conducted the experiments on FZD receptors and SB216763. J. P. S. generated the mCherry-MCT1 vector and critically modified the paper. L. R. D. conceived the project and wrote the paper with Z. L.

**References**

1. Becker, H. M., Mohebbi, N., Perna, A., Ganapathy, V., Capasso, G., and Wagner, C. A. (2010) Localization of members of MCT monocarboxylate transporter family Slc16 in the kidney and regulation during metabolic acidosis. *Am. J. Physiol. Renal Physiol.* **299**, F141–154

2. Cuff, M., Dyer, J., Jones, M., and Shirazi-Beechey, S. (2005) The human colonic monocarboxylate transporter isofrom 1: its potential importance to colonic tissue homeostasis. *Gastroenterology* **128**, 676–686

3. Doherty, J. R., and Cleveland, J. L. (2013) Targeting lactate metabolism for cancer therapeutics. *J. Clin. Invest.* **123**, 3685–3692

4. Lee, Y., Morrison, B. M., Li, Y., Lengacher, S., Farah, M. H., Hoffman, P. N., Liu, Y., Tsingalia, A., Jin, L., Zhang, P. W., Pellerin, L., Magistretti, P. J., and Rothstein, J. D. (2012) Oligodendroglia metabolically support axons and contribute to neurodegeneration. *Nature* **487**, 443–448

5. McCullagh, K. J., Poole, R. C., Halestrap, A. P., O’Brien, M., and Bonen, A. (1996) Role of the lactate transporter (MCT1) in skeletal muscles. *Am. J. Physiol. Renal Physiol.* **271**, F141–154

6. Murray, C. M., Hutchison, R., Bantick, J. R., Belfield, G. P., Benjamin, A. D., Brazma, D., Bundick, R. V., Cook, I. D., Craggs, R. I., Edwards, S., Evans, L. R., Harrison, R., Holness, E., Jackson, A. P., Jackson, C. G., Kingsman, L. P., Perry, M. W., Ross, A. R., Rugman, P. A., Sidhu, S. S., Sullivan, M., Taylor-Fishwick, D. A., Walker, P. C., Whitehead, Y. M., Wilkinson, D. J., Wright, A., and Donald, D. K. (2005) Monocarboxylate transporter MCT1 is a target for immunosuppression. *Nat. Chem. Biol.* **1**, 371–376

7. Suzuki, A., Stern, S. A., Bozdagi, O., Huntley, G. W., Walker, R. H., Magistretti, P. J., and Alberini, C. M. (2011) Astrocyte-neuron lactate transport is a target for immunosuppression. *PloS ONE* **5**, e13741

8. Smith, J. P., and Drewes, L. R. (2006) Modulation of monocarboxylic acid transporter-1 kinetic function by the cAMP signaling pathway in brain endothelial cells. *Dev. Cell* **14**, 810–823

9. Daneman, R., Zhou, L., Agulli, D., Cahoy, J. D., Kaushal, A., and Barres, B. A. (2010) The mouse blood-brain barrier transcriptome: a new resource for understanding the development and function of brain endothelial cells. *PloS ONE* **5**, e13741

10. Gerhart, D. Z., Enerson, B. E., Zhurinsky, J., Simcha, I., Albanese, C., D’Amico, M., Pestell, R. A., and Harik, S. I. (1991) Defective glucose transport across the blood-brain barrier as a cause of persistent hypoglycorrhachia, seizures, and developmental delay. *N. Engl. J. Med.* **325**, 703–709

11. Biel, M., and Yagen, B. (2007) Valproic acid: second generation. *Neurotherapeutics* **4**, 130–137

12. Miller, J. R., Rowning, B. A., Larabell, C. A., Yang-Snyder, J. A., Bates, R. L., and Moon, R. T. (1999) Establishment of the dorsal-ventral axis in Xenopus embryos coincides with the dorsal enrichment of dehydrogenase that is dependent on cortical rotation. *J. Cell Biol.* **146**, 427–437

13. MacDonald, B. T., Tamai, K., and He, X. (2009) Wnt/β-catenin signaling in proliferation in the developing mid-/hindbrain region. *Mol. Cell. Neuropathol.* **26**, 101–111

14. Bialer, M., Wang, T., Possemato, R., Yilmaz, O. H., Koch, C. E., Chen, W. W., Hutchins, A. W., Gultekin, Y., Peterson, T. R., Carette, J. E., Brummelkamp, T. R., Clish, C. B., and Sabatini, D. M. (2013) MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors. *Nat. Genet.* **45**, 104–108

15. Luehn, S., Corada, M., Bangsw, T., Babbage, J., Taddei, A., Czupalla, C. J., Reis, M., Felici, A., Wolburg, H., Fruttiger, M., Taketo, M. M., von Melchner, H., Plate, K. H., Gerhardt, H., and Dejana, E. (2008) Wnt/β-catenin signaling controls development of the blood-brain barrier. *J. Cell Biol.* **183**, 409–417

16. De Giorgis, V., and Veggiotti, P. (2013) GLUT1 deficiency syndrome 2013: multiple outcomes. *J. Clin. Invest.* **123**, 441–443

17. Lim, J. C., Kania, K. D., Wijesuriya, H., Chawla, S., Sethi, J. K., Pulaski, L., Romero, I. A., Couraud, P. O., Weksler, B. B., Hladky, S. B., and Barrand, M. A. (2009) Correlation of cerebral metabolites with functional outcome in experimental primate stroke using 1H-magnetic resonance spectroscopy. *Prog. Neurobiol.* **88**, 163–221

18. Panhuysen, M., Vogt-Weisenhorn, D. M., Blanquet, V., Brodski, C., Heinze, M. A., Beisler, W., and Wurst, W. (2004) Effects of Wnt1 signaling on proliferation in the developing mid-/hindbrain region. *Mol. Cell. Neuropathol.* **26**, 101–111

19. MacDonald, B. T., Tamai, K., and He, X. (2009) Wnt/β-catenin signaling: components, mechanisms, and diseases. *Dev. Cell* **17**, 9–26

20. Angers, S., and Moon, R. T. (2009) Proximal events in Wnt signal transduction. *Nat. Rev. Mol. Cell Biol.* **10**, 468–477

21. He, T. C., Sparks, A. B., Rago, C., Hermeking, H., Zawel, L., da Costa, L. T., Morin, P. J., Vogelstein, B., and Kinzler, K. W. (1998) Identification of c-MYC as a target of the APC pathway. *Science* **281**, 1509–1512

22. Hovanes, L., Li, T. W., Munguia, J. E., Truong, T., Milovanovic, T., Lawrence, Marsh, J., Holcombe, R. F., and Waterman, M. L. (2001) β-Catenin-sensitive isoforms of lymphoid enhancer factor-1 are selectively expressed in colon cancer. *Nat. Genet.* **28**, 53–57

23. Allison, M. A., and Tournier, L. (2009) Activation of β-catenin signaling by GSK-3 inhibition increases p-glycoprotein expression in brain endothelial cells. *J. Neurochem.* **106**, 1855–1865

24. Shuttmann, M., Zabinski, J., Simcha, I., Albanese, C., D’Amico, M., Pestell, R., and Ben-Ze’ev, A. (1999) The cyclin D1 gene is a target of the β-catenin/LEF-1 pathway. *Proc. Natl. Acad. Sci. U.S.A.* **96**, 5522–5527

25. He, R. S. (2003) Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes. *Trends Pharmacol. Sci.* **24**, 441–443

26. Park, C. H., Chang, J. Y., Hahn, E. R., Park, S., Kim, H. Y., and Yang, C. H. (2005) Quercetin, a potent inhibitor against β-catenin/Tcf signaling in SW480 colon cancer cells. *Biochem. Biophys. Res. Commun.* **328**, 227–234

27. Ayyanan, A., Civenni, G., Carlioni, L., Morel, C., Mueller, N., Lefort, K.,
Regulation of MCT1 by the Wnt/β-Catenin and Notch Pathways

Mandinova, A., Raffoul, W., Fiche, M., Dotto, G. P., and Briskin, C. (2006) Increased Wnt signaling triggers oncoenic conversion of human breast epithelial cells by a Notch-dependent mechanism. *Proc. Natl. Acad. Sci. U.S.A.* **103**, 3799–3804

37. Camps, J., Pitt, J. I., Emons, G., Hummon, A. B., Case, C. M., Grade, M., Jones, T. L., Nguyen, Q. T., Ghadimi, B. M., Beissbarth, T., Dillipippantono, M. J., Caplen, N. J., and Ried, T. (2013) Genetic amplification of the NOTCH modulator LNX2 upregulates the WNT/β-catenin pathway in colorectal cancer. *Cancer Res.* **73**, 2003–2013

38. Kim, H. A., Koo, B. K., Cho, J. H., Kim, Y. Y., Seong, J., Chang, H. I., Oh, Y. M., Stange, D. E., Park, J. G., Hwang, D., and Kong, Y. G. (2012) Notch1 counteracts WNT/β-catenin signaling through chromatin modification in colorectal cancer. *J. Clin. Invest.* **122**, 3248–3259

39. Kwon, C., Cheng, P., King, I. N., Andersen, P., Shenje, L., Nigam, V., and Bray, S. J. (2006) Notch signalling: a simple pathway becomes complex. *Nat. Rev. Mol. Cell Biol.* **7**, 135–146

40. Peignon, G., Durand, A., Cacheux, W., Ayrault, O., Terris, B., Laurent-Puig, P., Shroyer, N. F., Van Seuningen, I., Honjo, T., Perret, C., and Romagnolo, B. (2011) Complex interplay between β-catenin signalling and Notch effectors in intestinal tumorigenesis. *Gut* **60**, 166–176

41. Rodilla, V., Villanueva, A., Obrador-Hevia, A., Robert-Moreno, A., Fernández-Mañas, Y., Girilli, A., López-Bigas, N., Bellora, N., Alba, M. M., Torres, F., Duňach, M., Sanjuan, X., González, S., Gridley, T., Capella, G., Bigas, A., and Espinosa, I. (2009) Jagged1 is the pathological link between Wnt and Notch pathways in colorectal cancer. *Proc. Natl. Acad. Sci. U.S.A.* **106**, 6315–6320

42. Kopan, R., and Ilagan, M. X. (2009) The canonical Notch signaling pathway: unfolding the activation mechanism. *Cell* **137**, 216–233

43. Bray, S. J. (2006) Notch signalling: a simple pathway becomes complex. *Nat. Rev. Mol. Cell Biol.* **7**, 678–689

44. Dong, Y., Jesse, A. M., Kohn, A., Gunnell, L. M., Honjo, T., Zuscik, M. J., Roux, F., Durieu-Trautmann, O., Chaverot, N., Claire, M., Mailly, P., Bourre, O., Ribi, A., and Gavosto, S. (2006) Notch signalling: a simple pathway becomes complex. *Nat. Rev. Mol. Cell Biol.* **7**, 678–689

45. Piper, R. C., and Lehner, P. J. (2011) Endosomal transport via ubiquitination. *Trends Cell Biol.* **21**, 647–655

46. Saeki, Y., and Tanaka, K. (2008) Cell biology: two hands for degradation. *Nature* **453**, 460–461

47. Lu, C., Pribanic, S., Debonneville, A., Jiang, C., and Rotin, D. (2007) The PY motif of ENaC, mutated in Liddle syndrome, regulates channel internalization, sorting and mobilization from subapical pool. *Traffic* **8**, 1246–1264

48. Storch, S., Pohl, S., and Braulke, T. (2004) A dileucine motif and a cluster of acidic amino acids in the second cytoplasmic domain of the batten disease-related CLN3 protein are required for efficient lysosomal targeting. *J. Biol. Chem.* **279**, 53625–53634

49. Xia, S., Dun, X. P., Hu, P. S., Kjaer, S., Zheng, K., Qian, Y., Solèn, C., Xu, T., Fredholm, B., Hökfelt, T., and Xu, Z. Q. (2008) Postendocytic traffic of the galanin R1 receptor: a lysosomal signal motif on the cytoplasmic terminus. *Proc. Natl. Acad. Sci. U.S.A.* **105**, 5609–5613

50. Corvera, S., Chawla, A., Chakrabarti, R., Joly, M., Buxton, I., and Czeh, M. P. (1994) A double leucine within the GLUT4 glucose transporter COOH-terminal domain functions as an endocytosis signal. *J. Cell Biol.* **126**, 979–989

51. Shewan, A. M., Marsh, B. J., Melvin, D. R., Martin, S., Gould, G. W., and James, D. E. (2000) The cytosolic C-terminus of the glucose transporter GLUT4 contains an acidic cluster endosomal targeting motif distal to the dileucine signal. *Biochem. J.* **350**, 99–107

52. Inoki, K., Ouyang, H., Zhu, T., Lindvall, C., Wang, Y., Zhang, S., Yang, Q., Bennett, C., Harada, Y., Stankunas, K., Wang, C. Y., He, X., MacDougald, O. A., You, M., Williams, B. O., and Guan, K. L. (2006) TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. *Cell* **126**, 955–968

53. Laplante, M., and Sabatini, D. M. (2009) mTOR signaling at a glance. *J. Cell. Biol.* **182**, 3589–3594

54. Chenal, J., and Pellerin, L. (2007) Noradrenaline enhances the expression of the neuronal monocarboxylate transporter MCT2 by translational activation via stimulation of PI3K/Akt and the mTOR/S6K pathway. *Neurochem. Int.* **102**, 389–397

55. Li, C., Zhang, T., Lu, Y., Cui, Z., Yu, M., Zhang, S., and Xue, X. (2011) Evidence of the cross talk between Wnt and Notch signaling pathways in non-small-cell lung cancer (NSCLC): Notch3-siRNA weakens the effect of LiCl on the cell cycle of NSCLC cell lines. *J. Cancer Res. Clin. Oncol.* **137**, 771–778

56. Reis, M., Czupalla, C. J., Ziegler, N., Devraj, K., Zinke, J., Seidel, S., Heck, R., Thom, S., Macas, J., Bockamp, E., Fruttiger, M., Taketo, M. M., Dimmeler, S., Plate, K. H., and Liebner, S. (2012) Endothelial Wnt/β-catenin signaling inhibits glioma angiogenesis and normalizes tumor blood vessels by inducing PDGF-B expression. *J. Exp. Med.* **209**, 1611–1627

57. Corada, M., Nyqvist, D., Orsenigo, F., Caprini, A., Giampietro, C., Taketo, M. M., Iruela-Arispe, M. L., Adams, R. H., and Dejana, E. (2010) The Wnt/β-catenin pathway modulates vascular remodeling and specification by upregulating Dll4/Notch signaling. *Dev. Cell* **18**, 938–949

58. Krebs, L. T., Xue, Y., Norton, C. R., Shutter, J. R., Maguire, M., Sundberg, J. P., Gallahan, D., Clossen, V., Kitajewski, J., Callahan, R., Smith, G. H., Stark, K. L., and Gridley, T. (2000) Notch signaling is essential for vascular morphogenesis in mice. *Genes Dev.* **14**, 1343–1352

59. Ping, L. K., and Gerhardt, H. (2009) Angiogenesis: a team effort coordinated by notch. *Dev. Cell* **16**, 196–208

60. Duarte, A., Hirashima, M., Benedito, R., Trindade, A., Diniz, P., Bekman, E., Costa, L., Henrique, D., and Rossant, J. (2004) Dosage-sensitive requirement for mouse DLL4 in artery development. *Genes Dev.* **18**, 2474–2478

61. Gale, N. W., Dominguez, M. G., Noguera, I., Pan, L., Hughes, V., Valenzuela, D. M., Murphy, A. J., Adams, N. C., Lin, H. C., Holash, J., Thurston, G., and Yancopoulos, G. D. (2004) Haploinsufficiency of 6-4 like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development. *Proc. Natl. Acad. Sci. U.S.A.* **101**, 15949–15954

62. Chalamalasetty, R. B., Dunty, W. C., Jr., Biris, K. K., Ajima, R., Iacovino, M., Beisaw, A., Feigenbaum, L., Chapman, D. L., Yoon, J. K., Kyba, M., and Yamaguchi, T. P. (2011) The Wnt3a/β-catenin target gene Mesogenin1 controls the segmentation clock by activating a Notch signalling program. *Nat. Commun.* **2**, 390

63. Vannucci, S. J., and Simpson, I. A. (2003) Developmental switch in brain nutrient transporter expression in the rat. *Am. J. Physiol. Endocrinol. Metab.* **285**, E1127–E1134

